1. Home
  2. TBPH vs KBDC Comparison

TBPH vs KBDC Comparison

Compare TBPH & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$13.86

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Kayne Anderson BDC Inc.

KBDC

Kayne Anderson BDC Inc.

HOLD

Current Price

$13.99

Market Cap

941.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBPH
KBDC
Founded
2013
2021
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
941.8M
IPO Year
2013
2018

Fundamental Metrics

Financial Performance
Metric
TBPH
KBDC
Price
$13.86
$13.99
Analyst Decision
Strong Buy
Buy
Analyst Count
5
5
Target Price
$18.50
$15.40
AVG Volume (30 Days)
782.6K
406.3K
Earning Date
05-07-2026
03-02-2026
Dividend Yield
N/A
13.59%
EPS Growth
N/A
N/A
EPS
0.88
1.67
Revenue
$15,386,000.00
N/A
Revenue This Year
$70.90
$193.84
Revenue Next Year
N/A
$9.00
P/E Ratio
$15.75
$8.38
Revenue Growth
N/A
N/A
52 Week Low
$7.90
$13.06
52 Week High
$21.03
$16.89

Technical Indicators

Market Signals
Indicator
TBPH
KBDC
Relative Strength Index (RSI) 27.74 52.70
Support Level $13.41 $13.54
Resistance Level $14.76 $14.33
Average True Range (ATR) 0.58 0.36
MACD -0.08 0.04
Stochastic Oscillator 11.29 82.03

Price Performance

Historical Comparison
TBPH
KBDC

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About KBDC Kayne Anderson BDC Inc.

Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.

Share on Social Networks: